This systematic review examined whether psilocybin improves anhedonia in unipolar (MDD) and bipolar depression, synthesizing 6 clinical and 6 preclinical (animal) studies identified through a February 2026 PubMed and Ovid database search.
Across all 6 clinical studies, anhedonia consistently decreased after psilocybin-assisted psychotherapy (measured by SHAPS or MADRS anhedonia factor); 2 RCTs (pooled n=274) showed greater anhedonia improvement vs. control or comparator. Animal studies also showed improved reward sensitivity and motivation after psilocybin.
Only 12 total studies were included (6 clinical, 6 animal), with small clinical sample sizes; anhedonia measurement varied widely across studies, and most clinical studies captured only consummatory pleasure rather than anticipatory or motivational dimensions.
Psilocybin-assisted psychotherapy shows early promise for reducing anhedonia in depression, but clinicians should view this as preliminary evidence requiring larger, well-controlled trials with standardized, comprehensive anhedonia measures before changing practice.
Explore related topics